Star Gold Corp. (SRGZ) ("the Company") is pleased to announce that it has been invited to present at the Emerging Growth Conference on4, 2026.
The OMNI-EGFR inhibitor BH-30643 produced a 45% objective response rate among patients with EGFR C797S–positive disease in the phase 1/2 SOLARA trial. Data presented at WCLC 2026 support the use of B7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results